Thumbnail Image
Publication

Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial

Ledermann, JA
; 
Oza, AM
; 
Lorusso, D
; 
Aghajanian, C
; 
Oaknin, A
; 
Dean, A
; 
Colombo, N
; 
Weberpals, JI
; 
Clamp, Andrew R
; 
Scambia, G
... show 10 more
Citations
Altmetric:
Abstract
Authors
Ledermann, JA
Oza, AM
Lorusso, D
Aghajanian, C
Oaknin, A
Dean, A
Colombo, N
Weberpals, JI
Clamp, Andrew R
Scambia, G
Leary, A
Holloway, RW
Gancedo, MA
Fong, PC
Goh, JC
O'Malley, DM
Armstrong, DK
Banerjee, S
Garcia-Donas, J
Swisher, EM
Cameron, T
Maloney, L
Goble, S
Coleman, RL
Affiliation
Department of Oncology, UCL Cancer Institute, University College London and UCL Hospitals, London, UK.
Description
Date
2020
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Article
Citation
Ledermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(5):710-22.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/622981
Embedded videos